本报讯(记者矫月)1月12日，港股上市公司美中嘉和医学技术发展集团股份有限公司(以下简称"美中嘉 和")发布人事公告。公告显示，付骁女士因到退休年龄和集团职务调整退任总裁一职，原美中嘉和AI业 务板块负责人姜伟先生正式接棒，出任集团新任总裁。 作为国内领先的肿瘤医疗集团，美中嘉和此次将帅印交给一位具有深厚投行背景且长期掌舵AI业务的 高管，被资本市场视为公司从"传统医疗服务"向"智能化肿瘤诊疗生态"全面转型的关键信号。 翻看姜伟先生的履历，其职业路径呈现出鲜明的"金融+科技+医疗"复合特征，这在传统医疗服务企业 的核心高管中并不多见。公告显示，现年45岁的姜伟拥有一份亮眼的教育背景及工作履历。北京大学毕 业后，他曾先后供职于安永会计师事务所和中金公司（601995），在投行与资本运作领域深耕近二十 年。2020年加入美中嘉和后，姜伟任旗下医疗AI业务主体——北京和信康科技CEO，成为医疗AI业务 的核心带头人。 美中嘉和拥有稀缺的线下肿瘤医院网络以及庞大的影像诊断数据。姜伟的上任，或许意味着美中嘉和将 加速把这些临床数据脱敏后转化为标准化的数据资产，用于训练更精准的垂类模型，甚至探索数据要素 的商业化可能。 ...

Core Viewpoint - The company, Spring Medical, is a leading domestic orthopedic medical device manufacturer specializing in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants. Group 1: Company Overview - Spring Medical is primarily engaged in the development, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow [2][5]. - The company has received registration certificates for surgical robots for hip and knee joint surgeries, as well as medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3]. - The company is recognized as a "specialized and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3]. Group 2: Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [9]. Group 3: Market Position and Shareholder Information - As of September 30, 2025, the number of shareholders in Spring Medical was 6,164, an increase of 4.12% compared to the previous period, with an average of 46,906 circulating shares per person, a decrease of 3.95% [8]. - The top circulating shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund A, both of which are new shareholders [9].

来源：新浪证券-红岸工作室 12月23日，春立医疗跌0.83%，成交额2299.61万元，换手率0.33%，总市值91.29亿元。 异动分析 医疗器械概念+智能医疗+牙科医疗+专精特新+京津冀一体化 1、公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司 主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊 柱类植入产品为脊柱内固定系统的全系列产品组合。 2、2024年10月9日互动易：我公司是一家专注于骨科医疗器械领域的高新技术企业，产品涵盖关节类、 脊柱类、运动医学类、创伤类等全系列骨科产品。同时公司已经取得了髋关节手术机器人、膝关节手术 机器人等产品的注册证，以及手术规划的"医学图像处理软件"。这些产品和软件的开发表明公司在智能 医疗等领域进行的布局和研发投入。 3、国内领先的骨科医疗器械厂商，春立医疗主营业务系植入性骨科医疗器械的研发、生产与销售，包 括口腔金属和隐形正畸 口腔种植和修复。 公司拟设计多孔钽定制个体化牙种植体产品并完成生产转 换， 目前处于设计送检阶段。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级 ...

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design inspection phase for a customized porous tantalum dental implant product [2][3] Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021. The company specializes in implantable orthopedic medical devices, with main products including joint prosthetics and spinal implants [7][8] - The company's product range includes joint prosthetics for hip, knee, shoulder, and elbow joints, as well as a full series of spinal internal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [8] Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong innovation capability and high market share [3] - The company has obtained registration certificates for hip and knee surgical robots and medical image processing software, showcasing its investment in smart medical technology [2][3] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

Core Viewpoint - Spring Medical experienced a decline of 5.18% on November 21, with a trading volume of 61.44 million yuan and a market capitalization of 9.275 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its public listing on December 30, 2021 [7][8] Product and Market Position - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, along with a full range of spinal internal fixation systems [2][8] - The company has obtained registration certificates for surgical robots for hip and knee joint surgeries, as well as medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [9] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Spring Medical was 6,164, an increase of 4.12% from the previous period, while the average circulating shares per person decreased by 3.95% [8] - The stock has seen a net outflow of 4.90 million yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5]

Core Viewpoint - Spring Medical experienced a decline of 1.21% on November 13, with a trading volume of 101 million yuan and a market capitalization of 10.61 billion yuan [1] Group 1: Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company has developed a customized porous tantalum dental implant product, which is currently in the design and inspection phase [2] - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, along with a full range of spinal internal fixation systems [2][5] Group 2: Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [8] Group 3: Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3] - The company is located in the Tongzhou Economic Development Zone in Beijing and was established on February 12, 1998, with its listing date on December 30, 2021 [7]